INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers..

。。

Uncontrolled cell growth is a common feature in most tumor types and is a driving force in the formation of tumors. Genetic alterations like mutations or amplifications in the genes encoding the regulatory machinery of cell division contribute to malignant growth in a significant fraction of all solid tumors.

不受控制的细胞生长是大多数肿瘤类型的共同特征，并且是肿瘤形成的驱动力。编码细胞分裂调控机制的基因中的突变或扩增等遗传改变导致所有实体瘤中很大一部分的恶性生长。

That is why Boehringer Ingelheim is targeting the proteins involved in this process, a promising strategy for new cancer treatments..

这就是为什么勃林格殷格翰针对这一过程中涉及的蛋白质，这是一种有前途的新癌症治疗策略。。

Current methods targeting cyclin-dependent kinases can be limited by low selectivity and toxicity. Circle has developed a possible solution to these challenges by creating macrocycle therapies that directly inhibit cyclins, the proteins that regulate cell division.

目前针对细胞周期蛋白依赖性激酶的方法可能受到低选择性和毒性的限制。Circle通过创建直接抑制细胞周期蛋白（调节细胞分裂的蛋白质）的大环疗法，为这些挑战开发了一种可能的解决方案。

“We're delighted to be joining forces with Circle's scientists to develop an innovative cancer treatment based on their proprietary macrocycle platform molecules to achieve our goal of transforming the lives of people living with cancer,” said Clive R. Wood, Ph.D., Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim.

勃林格殷格翰高级副总裁兼发现研究全球负责人克莱夫·伍德博士说：“我们很高兴能与Circle的科学家合作，开发一种基于其专有大环平台分子的创新癌症治疗方法，以实现我们改变癌症患者生活的目标。”。

“This new collaboration complements our oncology research portfolio, and further reinforces our commitment to tackling intractable targets.”.

“这项新的合作补充了我们的肿瘤学研究组合，并进一步加强了我们对解决棘手目标的承诺。”。

David Earp, Ph.D., JD, chief executive officer, Circle Pharma said, “With our lead program, CID-078, a Cyclin A/B RxL inhibitor, we have demonstrated the capability of our MXMOTM platform to deliver oral macrocycles against a target that was previously considered to be undruggable. We’re excited to partner with Boehringer Ingelheim to leverage the platform against another challenging cyclin target that offers the potential to address high unmet need cancer indications.”.

Circle Pharma首席执行官David Earp博士说：“通过我们的领先项目CID-078（一种细胞周期蛋白a/B RxL抑制剂），我们已经证明了我们的MXMOTM平台能够针对以前被认为是不可治疗的靶标提供口服大环化合物。我们很高兴与勃林格殷格翰合作，利用该平台对抗另一个具有挑战性的细胞周期蛋白靶标，该靶标具有解决高度未满足需求的癌症适应症的潜力。”。

This partnership is a significant step toward Boehringer Ingelheim’s goal of transforming cancer care. It bolsters the already robust oncology pipeline of cancer cell-directed and immuno-oncology investigational therapies for smart combinations that may offer the greatest benefit for people living with cancer..

这种合作关系是朝着勃林格殷格翰转变癌症治疗目标迈出的重要一步。它支持了已经强大的肿瘤细胞导向和免疫肿瘤学研究疗法的肿瘤学管道，这些疗法可以为癌症患者提供最大的益处。。

As part of the agreement, Circle Pharma will receive an upfront payment and potential development, regulatory, and sales milestone payments of up to USD $607 million.

作为协议的一部分，Circle Pharma将获得高达6.07亿美元的预付款和潜在开发、监管和销售里程碑付款。

About Boehringer Ingelheim in oncology

关于勃林格殷格翰肿瘤学

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Boehringer Ingelheim’s generational commitment to driving scientific innovation is reflected by the company’s robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches.

我们有一个明确的愿望——通过取得有意义的进展来改变癌症患者的生活，最终目标是治愈一系列癌症。勃林格殷格翰（Boehringer Ingelheim）世代致力于推动科学创新，这一点反映在该公司强大的癌细胞导向和免疫肿瘤学研究疗法管道上，以及这些方法的巧妙结合上。

Boehringer’s ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations..

勃林格在肿瘤学方面的雄心壮志是采取勤奋而广泛的方法，创建一个合作研究网络，以挖掘多元化的思想，这对于解决一些最具挑战性但可能最具影响力的癌症研究领域至关重要。简而言之，对于勃林格殷格翰来说，癌症护理是个人的，无论是今天还是未来的几代人。。

About Boehringer Ingelheim

关于勃林格殷格翰

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain.

勃林格殷格翰是一家活跃于人类和动物健康领域的生物制药公司。作为该行业研发领域的最大投资者之一，该公司专注于开发创新疗法，以改善和延长未满足医疗需求的地区的寿命。自1885年成立以来，勃林格一直保持着长期的独立性，将可持续性贯穿于整个价值链。

More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com/uk (UK) or https://www.boehringer-ingelheim.com (rest of world)..

超过53500名员工服务于130多个市场，以建立一个更健康、更可持续和公平的明天。了解更多信息，请访问https://www.boehringer-ingelheim.com/uk（英国）或https://www.boehringer-ingelheim.com（世界其他地区）。。

About Circle Pharma

关于Circle Pharma

South San Francisco-based Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs.

。Circle Pharma的MXMO™平台结合了基于结构的合理药物设计和先进的合成化学，开发了新一代大环疗法，以应对挑战性目标，以满足未满足的临床需求。

Circle Pharma is focusing its development efforts on cyclins, which are master regulators of the machinery that controls the progression of cells through the cell cycle and are key drivers in many cancers. The company’s lead candidate, CID-078, is currently in clinical trials as part of a growing pipeline of novel macrocycle therapeutics..

Circle Pharma将其开发工作重点放在细胞周期蛋白上，细胞周期蛋白是控制细胞在细胞周期中进展的主要调节因子，也是许多癌症的关键驱动因素。该公司的主要候选药物CID-078目前正在进行临床试验，作为不断增长的新型大环类药物管道的一部分。。

To learn more about Circle Pharma, please visit www.circlepharma.com.

欲了解更多有关Circle Pharma的信息，请访问www.circlepharma.com。